Tamibarotene, Azacitidine, and Venetoclax May Strengthen AML Armamentarium
Brian Ball, MD, discusses the significance of targeting RARA in AML, the rationale for SELECT-AML-1, and additional AML research that may contribute to the broadening treatment paradigm in the future.
Source: onclive.com